DMD and Duchenne muscular dystrophy: We demonstrated the first clinical study of exon skipping therapy using a phosphorothioate-oligonucleotide against dystrophin exon 19 and showed successful induction of exon skipping and dystrophin expression in skeletal muscle in a DMD patient (Patient 0) [8].